# SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector

> **NCT04939402** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 200 (estimated)

## Conditions studied

- SARS-CoV-2
- Covid19

## Interventions

- **DIAGNOSTIC_TEST:** Serological testing

## Key facts

- **NCT ID:** NCT04939402
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-05
- **Primary completion:** 2028-05
- **Final completion:** 2028-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939402, "SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04939402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*